Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (301-310 of 346) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Haematologica|December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
British Journal of Haematology|September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaWei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Cell|November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensatesGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Pageof 35

Showing results (301-310 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Haematologica|December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
British Journal of Haematology|September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaWei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Cell|November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensatesGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Pageof 35